Stay updated on Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page.

Latest updates to the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Washington as a study location under the Locations section. The page revision was updated to v3.3.3 and the HHS Vulnerability Disclosure entry was removed.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check35 days agoChange DetectedThe update shows Revision: v3.3.2 replacing v3.3.1 with no substantive changes to the study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedFooter shows revision updated from v3.2.0 to v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedThe page-level notice about government funding and NIH operating status has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check63 days agoChange DetectedThere are no additions or deletions between the two screenshots. The page content and study details appear unchanged.SummaryDifference0.4%

- Check92 days agoChange DetectedCore content updated with a government-status notice and a new software version (v3.2.0); older version tag (v3.1.0) removed.SummaryDifference4%

Stay in the know with updates to Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page.